US · Healthcare · Biotechnology
EPS came in at -0.67 against a street estimate of -0.63 — a miss of 6.3%.
Analysts rate Immunovant Inc a strong buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $46.88.
| Fund | Stake |
|---|---|
| FMR Inc | 8.25% |
| Deep Track Capital, LP | 5.61% |
| BlackRock Inc | 3.20% |
| Baker Bros Advisors LP | 2.66% |
| State Street Corp | 2.21% |
| TCG Crossover Management, LLC | 2.17% |
| Morgan Stanley - Brokerage Accounts | 1.89% |
| Vanguard Portfolio Management, LLC | 1.80% |
| Document | Date |
|---|---|
| Proxy statement · Q3 2026 | 2026-07-22 |
| Annual report FY2026 | 2026-05-20 |
| Results announced · Q2 2026 | 2026-05-20 |
| Quarterly report · Q4 2025 | 2026-02-06 |
| Results announced · Q1 2026 | 2026-02-06 |
| Company announcement · Q4 2025 | 2025-12-12 |
| Company announcement · Q4 2025 | 2025-12-11 |
| Quarterly report · Q3 2025 | 2025-11-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immunovant Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.